NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed.

UnknownNA

Sponsor: The Netherlands Cancer Institute

Conditions: Non-small-cell Lung Carcinoma

Interventions: biopsy, ctDAN analysis

Countries: Netherlands

Initially, patients with EGFR mutation positive NSCLC respond well to osimertinib, a third generation EGFR tyrosine kinase inhibitor (TKI), but eventually progress. Upon progression multiple resistance mechanisms have been described and new therapeutic strategies are being developed to target these resistance mechanisms. Thorough and complete osimertinib resistance analysis enables optimal treatment decision making and might identify new targets for molecular treatment, thereby potentially improving patient outcome.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed metastatic NSCLC, characterized by a sensitizing EGFR mutation.

  2\. Progressive disease, as assessed by the treating physician during osimertinib monotherapy.

  3\. Eligible for subsequent treatment. 4. Willing to undergo a histological biopsy and withdrawal of a blood sample for ctDNA analysis.

  5\. Technically possible to take a histological biopsy.

Exclusion Criteria:

\- 1. Osimertinib discontinuation before blood draw and / or histological tumor biopsy.

2\. Initiation of a new line of anticancer therapy before blood draw and / or histological tumor biopsy.

Locations (6)

Amsterdam, North Holland, Netherlands
Amsterdam, Netherlands
Groningen, Netherlands
Maastricht, Netherlands
Nijmegen, Netherlands
Rotterdam, Netherlands